
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Access to comprehensive care is key to successful care of children with special needs and their families, an American Academy of Pediatrics (AAP) report notes, and the AAP offers specific suggestions for how to accomplish this.
Access to comprehensive care is key to successful care of children with special needs and their families, an American Academy of Pediatrics (AAP) report notes, and the AAP offers specific suggestions for how to accomplish this.






